Introduction {#s1}
============

Gastroduodenal fistula (GDF) also known as double pylorus is a rare complication of peptic ulcer disease with a prevalence of approximately 0.02-0.08% and male predominance \[[@R01], [@R02]\]. These fistulae can be congenital or acquired \[[@R02]\]. They generally occur in the lesser curvature and connect the gastric antrum with the duodenal bulb \[[@R03]\]. While most of the previously reported cases have been seen in Asian countries, there have been case reports from other parts of the world including Greece and Peru \[[@R04]-[@R06]\]. Although *Helicobacter pylori* (*H. pylori*) and nonsteroidal anti-inflammatory drug (NSAID) use have been associated with the formation of the GDF, the actual mechanism of the condition is unknown. The outcome of GDF is variable. In most patients it remains open without any long-term complications while in some cases the two openings can combine to form one opening \[[@R07]\].

GDF is usually an incidental finding and, therefore, endoscopic follow-up of these cases prior to formation of the fistula is very rare \[[@R08]\]. Here, we present the case of a patient who initially presented with a prepyloric ulcer, had serial endoscopic examinations and demonstrated the transformation into GDF.

Case Report {#s2}
===========

A 65-year-old female with history of chronic alcohol use was hospitalized for sudden onset of hematemesis. She also reported few days of nausea and vomiting associated with worsening ascites. She denied any significant past medical history except for a ruptured ovarian cyst at age of 30 years that required emergent surgery. Patient had a long history of alcohol use (two glasses of vodka daily) for over 10 years. Physical exam showed scleral icterus, there was mild abdominal distention with epigastric tenderness, no hepatosplenomegaly was noted. No signs of encephalopathy or asterixis were seen. Blood test showed hemoglobin 10.4 × 10 g/dL, white blood cell count of 7.7 × 10^3^ cells/µL and platelet count of 190 × 10^3^ cells/µL. Her prothrombin time and international normalized ratio (INR) were elevated at 1.4 and 14.3 s, respectively. Liver function test showed aspartate transaminase 140 U/L, alanine transaminase 29 U/L, alkaline phosphatase 332 U/L, total bilirubin 9.6 mg/dL (direct 7.4 mg/dL, indirect 2.2 mg/dL). Few hours after admission, she developed an episode of hematemesis with drop in hemoglobin to 7.7 g/dL. Emergent endoscopy showed a non-bleeding 2 cm prepyloric gastric antral ulcer ([Fig. 1](#F1){ref-type="fig"}). Biopsy of the ulcer base was negative for malignancy or *H. pylori*.

![Endoscopic appearance of antral ulcer.](gr-13-121-g001){#F1}

Follow-up endoscopy at an interval of 6 weeks showed a healing prepyloric antral ulcer with mild portal hypertensive gastropathy ([Fig. 2](#F2){ref-type="fig"}). Patient had a repeat endoscopy at 4 months for persistent nausea and vomiting which again showed a healing antral ulcer. She continued to drink alcohol and was intermittently followed by her the primary care physician. She also reported daily NSAID use for abdominal pain and nausea. She had multiple emergency department (ED) visits for the same complaints and underwent repeat endoscopy which showed a duodenal ulcer ([Fig. 3](#F3){ref-type="fig"}). She was managed with pantoprazole twice daily and was advised to avoid NSAIDs and alcohol. She also underwent extensive workup for recurrent nausea and vomiting which were all unremarkable. Systemic disorders including but not limited to neurological cause, adrenal, parathyroid and diabetes were also ruled out.

![Endoscopic image 3 years from the initial scope showing granulation tissue at the site of healing ulcer.](gr-13-121-g002){#F2}

![Endoscopic image showing duodenal ulcer.](gr-13-121-g003){#F3}

She again presented to the ED for worsening nausea and vomiting associated with upper abdominal pain. Endoscopy, now 7 years from the discovery of the initial lesion, showed a GDF. The prepyloric antral ulcer had fistulized into the duodenal bulb creating the appearance of a double pylorus ([Fig. 4](#F4){ref-type="fig"}). Biopsy of the ulcer base was again negative for malignancy or *H. pylori*. *H. pylori* stool antigen and serum *H. pylori* antibody test were also negative. She was discharged on oral proton pump inhibitor and has been followed up with gastroenterology for management of Laennec's cirrhosis. With more frequent outpatient follow up, alcohol abstinence and use of acid-suppression medication, she had gradual improvement in her symptoms in about 1 - 2 months.

![Endoscopic image showing gastroduodenal fistula or double pylorus 7 years from index endoscopy.](gr-13-121-g004){#F4}

Discussion {#s3}
==========

GDF or double pylorus can be acquired or congenital \[[@R9]\]. When a GDF is identified on endoscopy, the likelihood of congenital origin is more if the patient is young with no history of peptic ulcer disease or other congenital abnormalities \[[@R03]\]. The first cases of GDF have been seen as autopsy findings or incidental findings during surgery \[[@R10]\]. Patients are generally asymptomatic; however, symptoms may range from gastrointestinal bleed to abdominal pain or vomiting \[[@R05]\]. Our patient reported a long history of intractable vomiting associated with abdominal pain. However, due to the history of underlying hepatic cirrhosis it is difficult to identify the actual cause of her symptoms.

The mechanism of formation of GDF is unknown, however, there have been some interesting theories proposed in the past. One of them includes the rare possibility of concomitant duodenal as well as a gastric ulcer that perforated into one another \[[@R10]\]. An alternate theory states that gastric scarring due to gastric ulcer can cause the pylorus to draw up to the lesser curvature with subsequent perforation into the first part of the duodenum \[[@R10]\]. The mechanism of fistula formation in our patient is likely due to fistulization from the gastric antral ulcer during healing. GDF has been associated with systemic diseases such as systemic lupus erythematosus, diabetes, and chronic obstructive pulmonary disease \[[@R11]\]. Medications such as NSAID and steroids have also been associated with interfering with ulcer healing and subsequent development of the fistula \[[@R05], [@R11], [@R12]\]. Our patient did not report NSAID use during the initial finding of the prepyloric antral ulcer, however, during her outpatient visits in the following year she reported daily NSAID use for abdominal pain and nausea.

In terms of outcome, GDF remains open in most patients without further complications; however, there have been cases of spontaneous closure reported. Jeon et al reported a case of a 44-year-old Korean male who presented with weight loss and melena, and was found to have a GDF on endoscopy, likely due to previous gastric ulcer \[[@R9]\]. He was treated with proton pump inhibitor and follow-up endoscopy 1 month later showed complete closure of the fistula \[[@R9]\]. There have also been rare cases reported where the two openings have converged to form one large gastroduodenal passage \[[@R13]\]. In terms of management, GDF generally does not require invasive surgical management \[[@R14]\]. Surgery may be indicated if there is no improvement in symptoms with medical therapy or in case of recurrent bleeding, obstruction or perforation \[[@R15]\]. Management primarily involves acid suppression with proton pump inhibitors or histamine H2 receptor blockers and *H. pylori* eradication \[[@R12]\]. Additionally, avoidance of NSAIDs and other medications that may impair ulcer healing plays an important part in management \[[@R12]\].

In conclusion, acquired GDF is a rare and often incidental finding during endoscopy. Once identified, it is important to avoid risk factors associated with GDF to avoid complications. Additionally, if there is no improvement with medical management then patients may need surgical intervention. Our case documented serial endoscopies of a patient leading up to the fistula. The likely cause of her GDF was alcohol and NSAID use. She showed significant improvement in her symptoms about 1 - 2 months after starting acid suppression medications.
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